Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Keryx Biopharmaceuticals has reported a net loss of $5.47m, or $0.08 per share, for the third quarter ended 30 September 2012 compared to a net loss of $10.25m, or $0.15 per share, for the third quarter ended 30 September 2011.
Subscribe to our email newsletter
Operating loss for third quarter of 2012 was $5.53m compared to operating loss of $10.35m for the third quarter of 2011.
The company reported a net loss of $16.09m, or $0.22 per share, for the nine months ended 30 September 2012 compared to a net loss of $19.75m, or $0.30 per share, for the nine months ended 30 September 2011.
Operating loss of $20.40m was reported for the first nine months of 2012 compared to operating loss of $20.05m for the first nine months of 2011.
Keryx chief executive officer Ron Bentsur said the company is looking forward to reporting the top-line data from its long-term Phase 3 study of Zerenex and anticipating the NDA filing for the indication in the first quarter of 2013.
"We are also excited to have recently initiated our Phase 2 study exploring Zerenex in the non-dialysis dependent chronic kidney disease setting, which we believe represents a substantial potential additional opportunity for Zerenex," Bentsur added.